BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Marcadia Biotech and Merck & Co., Inc. (MRK) Enter Strategic Collaboration


3/7/2008 6:45:45 AM

INDIANAPOLIS--(BUSINESS WIRE)--Marcadia Biotech, Inc., a privately held drug development company, today announced a strategic collaboration with Merck & Co., Inc. to jointly discover, develop and commercialize novel biopharmaceutical therapies targeting the glucagon and related receptors for the treatment of diabetes and obesity.

“Merck is a world leader in the discovery of breakthrough medicines and has proven expertise in the development and commercialization of drugs that treat metabolic diseases,” said Fritz French, CEO of Marcadia. “We are excited about the opportunity to significantly leverage the research we have accomplished to date through this collaboration with Merck.”

Certain of the Marcadia intellectual property subject to the Merck collaboration was licensed from the Indiana University Research and Technology Corporation, and the company sponsors ongoing discovery research at the Indiana University Chemistry Department in Bloomington, Indiana in the therapeutic area of metabolic diseases.

“Marcadia has generated a unique collection of peptide drug candidates with potentially novel therapeutic attributes," said Luciano Rossetti, M.D., senior vice president and franchise head, Diabetes/Obesity and Cardiovascular at Merck Research Laboratories. “This latest collaboration underscores our strategy to establish a robust early-stage pipeline that delivers superior diabetes and obesity therapies."

Under the terms of the agreement Merck will pay Marcadia an initial upfront fee as well as payments for exclusivity and ongoing collaborative research. Marcadia will also be eligible to receive future milestone and royalty payments associated with research, development and commercialization of certain drug candidates. Merck has obtained a worldwide exclusive license to certain Marcadia development candidates and intellectual property. Marcadia will also have the right to exercise options for profit and cost sharing and co-promotion in the United States. Additional terms of the agreement were not disclosed. This transaction is subject to clearance under the United States Hart-Scott-Rodino Antitrust Improvements Act.

About Marcadia Biotech

Marcadia Biotech is a biopharmaceutical company focused on developing therapeutic products that will greatly improve the daily life of people with diabetes and obesity. Utilizing proprietary peptide chemistry, the company has a portfolio of compounds in its discovery and development pipeline. For more information about the company, visit www.marcadiabiotech.com.

Contact: Marcadia Biotech Fritz French, CEO, 317-566-2266 ext. 1 fritz@marcadiabiotech.com

Source: Marcadia Biotech, Inc.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->